Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke

Pavel Rodriguez, Zhao Jiang, Shiliang Huang, Qiang Shen, Timothy Q. Duong

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Stroke is a leading cause of morbidity and mortality in the world. Low-dose methylene blue (MB), which has been used safely to treat methemoglobinemia and cyanide poisoning in humans, has energy enhancing and antioxidant properties. We tested the hypothesis that methylene blue treatment delays progression of at-risk tissue (ca. perfusion-diffusion mismatch) to infarct in permanent middle cerebral artery occlusion in rats at two MB treatment doses. Serial MRI was used to evaluate MB treatment efficacy. The major findings were: (i) MB significantly prolonged the perfusion-diffusion mismatch, (ii) MB mildly increased the CBF in the hypoperfused tissue, (iii) MB did not change the final infarct volume in permanent ischemic stroke, and (iv) there were no dose-dependent effects on mismatch progression for the 1 and 3 mg/kg doses studied. This neuroprotective effect is likely the result of sustained ATP production and increased CBF to tissue at risk. This work has the potential to readily lead to clinical stroke trials given MB's excellent safety profile.

Original languageEnglish (US)
Pages (from-to)144-149
Number of pages6
JournalBrain Research
Volume1588
DOIs
StatePublished - Nov 7 2014

Fingerprint

Methylene Blue
Perfusion
Stroke
Methemoglobinemia
Middle Cerebral Artery Infarction
Cyanides
Neuroprotective Agents
Poisoning
Antioxidants
Adenosine Triphosphate
Clinical Trials
Morbidity
Safety
Mortality

Keywords

  • Infarct volume
  • Ischemic penumbra Neuroprotection
  • Middle-cerebral artery occlusion
  • MRI
  • Oxidative stress

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke. / Rodriguez, Pavel; Jiang, Zhao; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.

In: Brain Research, Vol. 1588, 07.11.2014, p. 144-149.

Research output: Contribution to journalArticle

Rodriguez, Pavel ; Jiang, Zhao ; Huang, Shiliang ; Shen, Qiang ; Duong, Timothy Q. / Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke. In: Brain Research. 2014 ; Vol. 1588. pp. 144-149.
@article{0308187ca6364c589033142858a60fb4,
title = "Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke",
abstract = "Stroke is a leading cause of morbidity and mortality in the world. Low-dose methylene blue (MB), which has been used safely to treat methemoglobinemia and cyanide poisoning in humans, has energy enhancing and antioxidant properties. We tested the hypothesis that methylene blue treatment delays progression of at-risk tissue (ca. perfusion-diffusion mismatch) to infarct in permanent middle cerebral artery occlusion in rats at two MB treatment doses. Serial MRI was used to evaluate MB treatment efficacy. The major findings were: (i) MB significantly prolonged the perfusion-diffusion mismatch, (ii) MB mildly increased the CBF in the hypoperfused tissue, (iii) MB did not change the final infarct volume in permanent ischemic stroke, and (iv) there were no dose-dependent effects on mismatch progression for the 1 and 3 mg/kg doses studied. This neuroprotective effect is likely the result of sustained ATP production and increased CBF to tissue at risk. This work has the potential to readily lead to clinical stroke trials given MB's excellent safety profile.",
keywords = "Infarct volume, Ischemic penumbra Neuroprotection, Middle-cerebral artery occlusion, MRI, Oxidative stress",
author = "Pavel Rodriguez and Zhao Jiang and Shiliang Huang and Qiang Shen and Duong, {Timothy Q.}",
year = "2014",
month = "11",
day = "7",
doi = "10.1016/j.brainres.2014.09.007",
language = "English (US)",
volume = "1588",
pages = "144--149",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke

AU - Rodriguez, Pavel

AU - Jiang, Zhao

AU - Huang, Shiliang

AU - Shen, Qiang

AU - Duong, Timothy Q.

PY - 2014/11/7

Y1 - 2014/11/7

N2 - Stroke is a leading cause of morbidity and mortality in the world. Low-dose methylene blue (MB), which has been used safely to treat methemoglobinemia and cyanide poisoning in humans, has energy enhancing and antioxidant properties. We tested the hypothesis that methylene blue treatment delays progression of at-risk tissue (ca. perfusion-diffusion mismatch) to infarct in permanent middle cerebral artery occlusion in rats at two MB treatment doses. Serial MRI was used to evaluate MB treatment efficacy. The major findings were: (i) MB significantly prolonged the perfusion-diffusion mismatch, (ii) MB mildly increased the CBF in the hypoperfused tissue, (iii) MB did not change the final infarct volume in permanent ischemic stroke, and (iv) there were no dose-dependent effects on mismatch progression for the 1 and 3 mg/kg doses studied. This neuroprotective effect is likely the result of sustained ATP production and increased CBF to tissue at risk. This work has the potential to readily lead to clinical stroke trials given MB's excellent safety profile.

AB - Stroke is a leading cause of morbidity and mortality in the world. Low-dose methylene blue (MB), which has been used safely to treat methemoglobinemia and cyanide poisoning in humans, has energy enhancing and antioxidant properties. We tested the hypothesis that methylene blue treatment delays progression of at-risk tissue (ca. perfusion-diffusion mismatch) to infarct in permanent middle cerebral artery occlusion in rats at two MB treatment doses. Serial MRI was used to evaluate MB treatment efficacy. The major findings were: (i) MB significantly prolonged the perfusion-diffusion mismatch, (ii) MB mildly increased the CBF in the hypoperfused tissue, (iii) MB did not change the final infarct volume in permanent ischemic stroke, and (iv) there were no dose-dependent effects on mismatch progression for the 1 and 3 mg/kg doses studied. This neuroprotective effect is likely the result of sustained ATP production and increased CBF to tissue at risk. This work has the potential to readily lead to clinical stroke trials given MB's excellent safety profile.

KW - Infarct volume

KW - Ischemic penumbra Neuroprotection

KW - Middle-cerebral artery occlusion

KW - MRI

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84909987563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909987563&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2014.09.007

DO - 10.1016/j.brainres.2014.09.007

M3 - Article

C2 - 25218555

AN - SCOPUS:84909987563

VL - 1588

SP - 144

EP - 149

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -